Drug Discovery World

DECEMBER 21, 2023

Other biotechnologies coming to the fore this year were antibody-drug conjugates and CRISPR gene editing. Three trends in the antibody-drug conjugate (ADC) market Antibody-drug conjugates are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker.

Gene Therapy 59

Gene Therapy Gene Antibody FDA Approval 59

Pharmaceutical Technology

FEBRUARY 15, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Gene Splicing 130

Gene Splicing Gene Recombinant DNA Technology DNA 130

Pharmaceutical Technology

FEBRUARY 15, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. These animals have been used as a key tool in functional genomics to generate models for human diseases and to validate new drugs.

Genetics 130

Genetics DNA Antibody Genome 130

XTalks

JUNE 16, 2023

Cetuximab, an anti-epidermal growth factor receptor (anti-EGFR) antibody with FDA approval for metastatic colorectal cancer, is effective in conjunction with encorafenib. A negative result from a plasma specimen does not rule out genomic findings in a patient’s tumor. The global companion diagnostics market was valued at $6.8

FDA Approval 97

FDA Approval Genome Genomics DNA 97

pharmaphorum

DECEMBER 5, 2022

The French biotech says VLA1553 met its objective in the phase 3 study, with 99% of patients exhibiting an antibody response against the virus 12 months after receiving a single dose of the shot, with no evidence of a tailing off in levels in the last six months. It will continue for up to five years.

Vaccination 96

Vaccination Vaccine Antibody Allergies 96

Drug Discovery World

OCTOBER 5, 2023

This free 2-hour Summit will take place online and will outline areas of advancement and opportunity in the cancer research market. Find out the answer to questions such as: Where is the opportunity in the cancer research market? More to be announced. What are the best research tools to aid development of new treatments and vaccines?

Research 52

Research Antibody Medicine RNA 52

Drug Discovery World

FEBRUARY 12, 2024

“In the upcoming year, we will see the expansion of new, more complex markets and updated requirements from regulators. Without fixing the current, broken PV models, the continuous cycle of more complexity in the market, which then pushes organisations to incorporate automation into insufficient processes, will massively hinder PV operations.

Genome 139

Genome Genomics Life Science Gene Therapy 139

The Pharma Data

DECEMBER 17, 2020

MacroGenics, a biopharma company working to make cancer history with the development of innovative monoclonal antibody-based therapeutics, had its first product , MARGENZA , approved by the FDA on Wednesday. at the time of the announcement. The product launch is expected to take place in March of 2021. Athenex, Inc.

FDA Approval 52

FDA Approval Genome Genomics Production 52

pharmaphorum

OCTOBER 4, 2022

AstraZeneca’s rare disease firm Alexion is set to expand its genomic medicine portfolio with the acquisition of gene editing specialist LogicBio Therapeutics, in a deal worth approximately $68 million. The LogicBio deal is the latest in a string of acquisitions for AstraZeneca.

Gene Editing 62

Gene Editing Gene Genome Genomics 62

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.

Antibody 64

Antibody Engineer Protein Scientist 64

Drug Discovery World

MARCH 13, 2024

According to Statista, revenue in this sector is expected to grow at an annual rate of 6.77%, resulting in a market volume of US$2,208m by 2028 1. Singapore is also leading the way in genomics, having founded The Genome Institute of Singapore as far back as 2000.

Life Science 69

Life Science Genome Genomics Research 69

Pharmaceutical Technology

MARCH 9, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

In-Vivo 130

In-Vivo Antibody Genetics Gene 130

Drug Discovery World

NOVEMBER 14, 2023

The free two-hour summit will outline areas of opportunity in the oncology market and will provide a unique mix of expert presentations and lively panel discussion. Register for free to secure your place and to receive your exclusive download link after the event.

Research 52

Research Genome Genomics Antibody 52

Drug Discovery World

APRIL 25, 2024

The market for cell line development is currently rising due to an increased focus by the life sciences sector on biopharmaceuticals and targeted therapies. According to Grand View Research, the global cell line development market was valued at $4.81

Development 59

Development Protein In-Vivo Life Science 59

Drug Discovery World

NOVEMBER 2, 2023

The free two-hour summit will outline areas of opportunity in the oncology market and will feature insights from thought leaders in cancer research, precision medicine and immunotherapy. Register for free to secure your place and to receive your exclusive download link after the event.

Research 52

Research Genome Genomics Medicine 52

Drug Discovery World

MAY 25, 2023

Broughton: new inhalation testing service The service is designed to help pharmaceutical companies bring orally inhaled and nasal drug products (OINDPs) to market efficiently. The platform works with the SYNTAX Hi-Fidelity reagent kits for synthesising longer oligos.

Production 52

Production Reagent DNA Drugs 52

Drug Discovery World

MAY 13, 2024

Key to this is the ability to rapidly determine protein structures alone and in combination with antibodies or small molecules. This allows researchers to quickly view, for example, how many different antibodies are binding to a vaccine or virus. RA: How reliable are vaccines now for respiratory viruses such as flu?

Vaccination 59

Vaccination Vaccine Protein Antibody 59

Drug Discovery World

APRIL 29, 2024

He holds a PhD in Chemistry for early work on antibody drug conjugates in 1987 and was awarded the Bioprocessing Lifetime Achievement Award in 2021. She previously worked at Vertex Pharmaceuticals as VP Global Marketing, and at Zealand Pharma as VP, US Sales and Marketing.

Drugs 52

Drugs Sales Gene Therapy Life Science 52

Drug Discovery World

APRIL 15, 2024

The company has a biologics pipeline with a focus on differentiated antibodies targeting a range of indications. But we’ve never been able to be in that kind of design and test loop where it’s like, I have this hypothesis, I believe that if I design an antibody that has these attributes, it’s going to solve my biology.

Antibody 59

Antibody Drugs In-Vivo Life Science 59

Drug Discovery World

NOVEMBER 27, 2023

As the significance of large molecules continues to broaden across diverse modalities, emphasis on bispecific and multispecific antibodies to treat various disorders such as rheumatologic diseases, cancer, diabetes, anaemia, and infectious diseases becomes paramount. References Mistry RK, Kelsall E, Sou SN, et al.

Production 59

Production Engineer Gene Editing Gene 59

Drug Discovery World

OCTOBER 16, 2023

Alchemab, on the other hand, has developed a highly differentiated platform which enables the identification of novel drug targets and therapeutics by analysis of patient antibody repertoires, drawing from the expertise in Cambridge to progress the company’s mission to build a broad pipeline of protective therapeutics for hard-to-treat diseases.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Drug Discovery World

JULY 10, 2023

Think how cell and gene therapies or monoclonal antibodies have become targeted medicines for cancer and you’ll get an idea of the shifting pharmaceutical market. Its convergence with genomics makes sense and we have now multiple examples of AI being used to inform prescribing, diagnostics and drug discovery/ development.

Gene Therapy 52

Gene Therapy Gene Scientist Gene Editing 52

Drug Discovery World

NOVEMBER 15, 2022

Applications: The ability to synthesise longer, accurate DNA sequences opens up a vast array of application possibilities: generating CRISPR libraries, in situ hybridisation probes, antibody libraries, vaccines, and so on, along with the ability to engineer metabolic pathways, microbes, and plants. .

DNA 98

DNA Drugs Antibody Engineer 98

Delveinsight

JULY 30, 2020

Roche bets USD 120 Million on UCB’s anti-tau Alzheimer’s antibody. The Swiss pharma, Roche, is handing over USD 120 million upfront for the right of UCB’s anti-tau antibody development. ‘Genome-tuning’ biotech Omega Therapeutics snags USD 85 Million. GlaxoSmithKline, the U.S.

Genome 52

Genome Genomics Antibody Gene 52

pharmaphorum

SEPTEMBER 13, 2022

Thanks to the dedicated efforts of doctors, patients, carers, and healthcare professionals, people diagnosed with blood cancer are now living longer, with a steady stream of more effective treatments entering the market each year. 2012 – The 100,000 Genomics Project begins. 2016–2022 — New treatments enter the market.

Genome Project 88

Genome Project Genome Genomics DNA 88

Drug Discovery World

AUGUST 10, 2022

By Mark White, Associate Director of Biopharma Product Marketing at Bio-Rad and Marwan Alsarraj, Biopharma Segment Manager, Digital Biology Group. Next, the advent of antibody treatments in 1997 created the first targeted cancer therapy 2. Exactly three decades later, the first CAR T cell therapy hit the market.

Manufacturing 98

Manufacturing Gene Genome Genomics 98

Pharmaceutical Technology

DECEMBER 22, 2022

The main focus is the antibody-drug conjugate (ADC ), Enhertu (trastuzumab deruxtecan), which had already achieved regulatory approval as a second-line therapy for metastatic or recurrent HER2-positive breast cancer, as well as HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Insulin 130

Insulin Production Development Genetics 130

Pharmaceutical Technology

MAY 15, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Antibody 130

Antibody DNA Genome Genomics 130

pharmaphorum

JANUARY 24, 2023

Rather than be provided a therapy that has been tested across a broad range of the population, there are now many therapies on the market that are designed specifically to work for sub-populations within disease areas. The monoclonal antibody binds to the CD200R1 receptor, preventing the interaction of CD200 and CD200R1.

Genetics 85

Genetics Drugs Genome Project Biobanking 85

pharmaphorum

JANUARY 12, 2021

Dark Antigens represent a new class of cancer-associated antigens that derive from the genomic “dark matter” – the portion of the human genome that is normally not expressed as protein. These sequences are usually silenced in healthy cells but are activated and presented on tumour cells.

Genome 57

Genome Genomics Licensing Licensing 57

Cloudbyz

MARCH 6, 2024

For example, monoclonal antibodies, a type of biologic, can selectively bind to specific targets such as proteins or cells involved in disease processes, thereby modulating immune responses or inhibiting disease progression. One of the key features of biologics is their ability to mimic or augment natural biological processes within the body.

Gene 73

Gene Immune Response Manufacturing Gene Therapy 73

The Pharma Data

OCTOBER 14, 2020

Food and Drug Administration (FDA) to begin a Phase I clinical trial of hAd5-COVID-19, the company’s novel COVID-19 vaccine candidate that targets both the inner nucleocapsid (N), engineered to activate T cells, and outer spike (S) protein, engineered to activate antibodies against the coronavirus (SARS-CoV-2).

Antibody 52

Antibody Vaccination Vaccine Trials 52

Pharmaceutical Technology

APRIL 27, 2023

Genomic medicine development was ranked as the top industry trend for 2023 in a survey of 198 GlobalData Pharma clients and prospects conducted between October and November 2022. GlobalData pharmaceutical analysts project that RNA-based gene therapies for oncology will grow from zero in 2022 to $4.6 billion by 2028.

Manufacturing 130

Manufacturing RNA Contamination Vaccination 130

pharmaphorum

OCTOBER 20, 2021

It will attempt to validate the software by comparing its findings with clinical data such as brain imaging and genomics analyses to see if it can accurately detect neurocognitive impairments that can’t be found using current tests.

Trials 76

Trials Genome Genomics Bioinformatics 76

The Pharma Data

NOVEMBER 17, 2021

Nasdaq VIR) moment blazoned US government contracts totalling roughly$ 1 billion (1) (USD) to buy sotrovimab, an investigational monoclonal antibody for the early treatment of COVID-19, which the US Food and Drug Administration (FDA) granted Exigency Use Authorization (EUA) in May 2021. 1.617.2), Delta Plus (AY.1 2) and Mu (B.1.621).

Antibody 52

Antibody In-Vitro Vaccination Vaccine 52

Roots Analysis

MARCH 24, 2022

Scientific fields involved in high throughput measurement of biological molecules are referred with the suffix- omics including, transcriptomics, genomics, proteomics and metabolomics. Genomics is the study of genetic material within a cell, and transcriptomics is the study of gene activity in different cells. Web: [link].

Clinical Research 52

Clinical Research Development Research Drug Delivery Systems 52

pharmaphorum

JULY 13, 2022

The first subject has now been given a dose of VERVE-101, in what is thought to be the first test in humans of an experimental CRISPR/Cas9 genome editing technique known as base editing. Through base editing, drugs replace single nucleotide in the DNA strand with another, without making double-strand breaks (DSBs) in the gene.

Gene Editing 97

Gene Editing Trials Drugs Gene 97